227 related articles for article (PubMed ID: 35032444)
1. Prenatal exposure to teratogenic medications in the era of Risk Evaluation and Mitigation Strategies.
Sarayani A; Albogami Y; Thai TN; Smolinski NE; Patel P; Wang Y; Nduaguba S; Rasmussen SA; Winterstein AG
Am J Obstet Gynecol; 2022 Aug; 227(2):263.e1-263.e38. PubMed ID: 35032444
[TBL] [Abstract][Full Text] [Related]
2. Common teratogenic medication exposures-a population-based study of pregnancies in the United States.
Wang Y; Smolinski NE; Thai TN; Sarayani A; Ewig C; Rasmussen SA; Winterstein AG
Am J Obstet Gynecol MFM; 2024 Jan; 6(1):101245. PubMed ID: 38061552
[TBL] [Abstract][Full Text] [Related]
3. Prenatal Care Initiation and Exposure to Teratogenic Medications.
Winterstein AG; Wang Y; Smolinski NE; Thai TN; Ewig C; Rasmussen SA
JAMA Netw Open; 2024 Feb; 7(2):e2354298. PubMed ID: 38300617
[TBL] [Abstract][Full Text] [Related]
4. Identifying pregnancies in insurance claims data: Methods and application to retinoid teratogenic surveillance.
MacDonald SC; Cohen JM; Panchaud A; McElrath TF; Huybrechts KF; Hernández-Díaz S
Pharmacoepidemiol Drug Saf; 2019 Sep; 28(9):1211-1221. PubMed ID: 31328328
[TBL] [Abstract][Full Text] [Related]
5. Drugs associated with teratogenic mechanisms. Part I: dispensing rates among pregnant women in the Netherlands, 1998-2009.
van Gelder MM; Bos JH; Roeleveld N; de Jong-van den Berg LT
Hum Reprod; 2014 Jan; 29(1):161-7. PubMed ID: 24105826
[TBL] [Abstract][Full Text] [Related]
6. The teratogenesis risk associated with antiseizure medication duotherapy in women with epilepsy.
Vajda FJE; O'Brien TJ; Graham JE; Hitchcock AA; Perucca P; Lander CM; Eadie MJ
Epilepsy Res; 2024 Feb; 200():107316. PubMed ID: 38340680
[TBL] [Abstract][Full Text] [Related]
7. Teratogenic medications and concurrent contraceptive use in women of childbearing ability with epilepsy.
Bhakta J; Bainbridge J; Borgelt L
Epilepsy Behav; 2015 Nov; 52(Pt A):212-7. PubMed ID: 26460786
[TBL] [Abstract][Full Text] [Related]
8. Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations.
Charlton RA; Weil JG; Cunnington MC; Ray S; de Vries CS
Drug Saf; 2011 Feb; 34(2):157-71. PubMed ID: 21247222
[TBL] [Abstract][Full Text] [Related]
9. Pregnancy outcome after in utero exposure to valproate : evidence of dose relationship in teratogenic effect.
Diav-Citrin O; Shechtman S; Bar-Oz B; Cantrell D; Arnon J; Ornoy A
CNS Drugs; 2008; 22(4):325-34. PubMed ID: 18336060
[TBL] [Abstract][Full Text] [Related]
10. The estimation of human teratogenic/fetotoxic risk of exposures to drugs on the basis of Hungarian experience: a critical evaluation of clinical and epidemiological models of human teratology.
Czeizel AE
Expert Opin Drug Saf; 2009 May; 8(3):283-303. PubMed ID: 19505262
[TBL] [Abstract][Full Text] [Related]
11. Environmental causes of human congenital malformations: the pediatrician's role in dealing with these complex clinical problems caused by a multiplicity of environmental and genetic factors.
Brent RL
Pediatrics; 2004 Apr; 113(4 Suppl):957-68. PubMed ID: 15060188
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine-Topiramate to Prevent Exposure During Pregnancy.
Sarayani A; Donahoo WT; Hampp C; Brown JD; Winterstein AG
Ann Intern Med; 2023 Apr; 176(4):443-454. PubMed ID: 36940443
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of risk mitigation strategies to prevent fetal exposure to mycophenolate.
Sarayani A; Albogami Y; Elkhider M; Hincapie-Castillo JM; Brumback BA; Winterstein AG
BMJ Qual Saf; 2020 Aug; 29(8):636-644. PubMed ID: 31649165
[TBL] [Abstract][Full Text] [Related]
14. Drugs associated with teratogenic mechanisms. Part II: a literature review of the evidence on human risks.
van Gelder MM; de Jong-van den Berg LT; Roeleveld N
Hum Reprod; 2014 Jan; 29(1):168-83. PubMed ID: 24108217
[TBL] [Abstract][Full Text] [Related]
15. High-Risk Medication Prescriptions in Primary Care for Women Without Documented Contraception.
Panchal BD; Cash R; Moreno C; Vrontos E; Bourne C; Palmer S; Simpson A; Panchal AR
J Am Board Fam Med; 2019; 32(4):474-480. PubMed ID: 31300567
[TBL] [Abstract][Full Text] [Related]
16. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy.
Schaefer C; Meister R; Weber-Schoendorfer C
Arch Gynecol Obstet; 2010 Feb; 281(2):221-7. PubMed ID: 19444462
[TBL] [Abstract][Full Text] [Related]
17. Human teratogens update 2011: can we ensure safety during pregnancy?
Rasmussen SA
Birth Defects Res A Clin Mol Teratol; 2012 Mar; 94(3):123-8. PubMed ID: 22328359
[TBL] [Abstract][Full Text] [Related]
18. Pregnancy outcome following exposure to permethrin and use of teratogen information.
Kennedy D; Hurst V; Konradsdottir E; Einarson A
Am J Perinatol; 2005 Feb; 22(2):87-90. PubMed ID: 15731987
[TBL] [Abstract][Full Text] [Related]
19. Can we ensure the safe use of known human teratogens? Introduction of generic isotretinoin in the US as an example.
Honein MA; Moore CA; Erickson JD
Drug Saf; 2004; 27(14):1069-80. PubMed ID: 15554743
[TBL] [Abstract][Full Text] [Related]
20. Prescription of teratogenic medications in United States ambulatory practices.
Schwarz EB; Maselli J; Norton M; Gonzales R
Am J Med; 2005 Nov; 118(11):1240-9. PubMed ID: 16271908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
